yahoo_financeOriginal article
Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value?
EarningsnegativeNegative
AI Analysis
Summary
Myriad Genetics missed Q2 earnings and cut guidance, raising questions about valuation despite trading 54% below estimated fair value according to analyst assessment.
Financial Highlights
Guidance
lowered
Outcome Details
Missed Q2 results and cut guidance
Importance:5/10
Sentiment:
-0.70
earningsguidance cutvaluationQ2 results
Related Companies
Read the original article
Published by yahoo_finance on August 3, 2026 6:07 AM